Arca
Skip to content
Tools
Tools

Opioid receptors; mu/kappa/delta

Family in Homo sapiens that 10 drugs act on.

  • Drugs that act on it: 10
  • Approved: 8
  • In phases 1 to 3: 2
  • Sponsors: 8
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on OPRD1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 10

Approved8

  • Naloxone
  • Naltrexone
  • Codeine
  • Nalbuphine
  • Hydrocodone
  • Oxymorphone
  • Benzhydrocodone
  • Dextromoramide

Phase 31

  • Cebranopadol

Phase 21

  • Ondelopran

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Adneuris Therapeutics, Inc.110%
    • Clive Michelsen110%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 10 act as: Opioid receptors; mu/kappa/delta agonist; the rest name their own mechanism.
    NaloxoneApprovedADAPTSmall moleculeAntagonistOpioid receptors; mu/kappa/delta antagonist104
    NaltrexoneBoxed warningApprovedClive MichelsenSmall moleculeAntagonistOpioid receptors; mu/kappa/delta antagonist63
    CodeineWithdrawn Boxed warningApprovedHikma PharmaceuticalsSmall moleculeAgonist51
    NalbuphineBoxed warningApprovedPH HealthSmall moleculeAgonist37
    HydrocodoneBoxed warningApprovedMerck & Co. (MSD)Small moleculeAgonist23
    OxymorphoneBoxed warningApprovedEndo InternationalSmall moleculeAgonist3
    BenzhydrocodoneApproved—Small moleculeAgonist0
    DextromoramideApproved—Small moleculeAgonist0
    CebranopadolPhase 3Adneuris Therapeutics, Inc.Small moleculeAgonist2
    OndelopranPhase 2Eli LillySmall moleculeAntagonistOpioid receptors; mu/kappa/delta antagonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 40 in all, from ClinicalTrials.gov.
    A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy ParticipantsNalbuphinePhase 1RecruitingTrevi TherapeuticsNov 18, 2026
    Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot StudyCodeinePhase 2RecruitingShaukat Khanum Memorial Cancer Hospital & Research CentreNov 5, 2026
    The Study of Brave-LC LDN Treatment TrialNaloxone, NaltrexonePhase 3Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Nov 4, 2026
    Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Opioid Overdose (Trial 3 of 3)NaloxoneNot applicableNot yet recruitingState University of New York at BuffaloOct 15, 2026
    A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic PainCebranopadolPhase 2RecruitingAdneuris Therapeutics, Inc.Oct 15, 2026
    Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use DisorderNaloxone, NaltrexonePhase 1 / Phase 2Not yet recruitingClive MichelsenOct 13, 2026
    Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsNalbuphinePhase 3RecruitingTrevi TherapeuticsOct 9, 2026
    A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)Codeine, HydrocodonePhase 2RecruitingMerck Sharp & Dohme LLCOct 7, 2026
    A Pilot Study on the Efficacy of Oral Low Dose Naltrexone for VulvodyniaNaloxone, NaltrexonePhase 2Not yet recruitingUniversity of FloridaOct 7, 2026
    Effect of a Low-Dose Ketamine-Dexmedetomidine-Based Opioid-Sparing Anesthesia Protocol on Postoperative Quality of Recovery After Percutaneous NephrolithotomyNalbuphinePhase 4Not yet recruitingAssiut UniversityOct 2, 2026
    Impact of Entropy Monitoring on Anesthetic Consumption and Recovery After Laparoscopic CholecystectomyNalbuphineNot applicableRecruitingKRL Hospital, IslamabadSep 29, 2026
    An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical OriginCebranopadolPhase 3RecruitingAdneuris Therapeutics, Inc.Sep 28, 2026
    Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction ClinicsNaloxoneNot applicableNot yet recruitingVanderbilt University Medical CenterSep 24, 2026
    Ultrasound-Guided Ilioinguinal-Iliohypogastric Nerve Block Following Spinal Anesthesia Comparing Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Unilateral Inguinal Hernia RepairNalbuphinePhase 4Not yet recruitingAssiut UniversitySep 23, 2026
    Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNaltrexonePhase 4Not yet recruitingJing LuoSep 21, 2026
    Post-Vasectomy Pain StudyCodeinePhase 1RecruitingColumbia UniversitySep 17, 2026
    Nerve Block for Severe Abdominal Pain in the Emergency DepartmentHydrocodoneEarly phase 1RecruitingUniversity of California, IrvineSep 17, 2026
    Suzetrigine in Tonsillectomy for Opioid-sparing Pain ManagementCodeinePhase 4Not yet recruitingStanford UniversitySep 16, 2026
    Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid UsersCodeinePhase 4RecruitingViatris Inc.Sep 10, 2026
    A Clinical Trial of GRT7040 in Adults With Acute Pain Following BunionectomyCodeine, HydrocodonePhase 2Not yet recruitingGrünenthal GmbHSep 8, 2026
    Naloxone for In-Hospital Cardiac ArrestNaloxonePhase 2 / Phase 3Not yet recruitingRegion SkaneSep 8, 2026
    A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk Aim 3NaloxoneNot applicableRecruitingBoston Medical CenterSep 1, 2026
    Suzetrigine vs. Standard Care Pain Relief Following Outpatient Knee Replacement SurgeryHydrocodonePhase 4Not yet recruitingEndeavor HealthSep 1, 2026
    Pain Control With Ketorolac and Nerve Block After Wrist and Hand SurgeryCodeinePhase 4RecruitingUniversity of ChicagoAug 19, 2026
    Afentanil and Remifentanil for Anesthesia Quality and RecoveryNalbuphinePhase 4Not yet recruitingQianfoshan HospitalAug 12, 2026
    Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening SystemCodeineNot applicableEnrolling by invitationIntelligent Bio Solutions Inc.Aug 11, 2026
    Unilateral Spinal vs General Anaesthesia in Low EF Patients: A Hemodynamic ComparisonNalbuphine—Enrolling by invitationSargodha Medical CollegeAug 7, 2026
    Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity PharmacotherapyNaltrexoneNot applicableNot yet recruitingPhenomix SciencesJul 27, 2026
    Clinician Practice Companion to Address Youth Substance UseNaloxoneNot applicableNot yet recruitingMassachusetts General HospitalJul 24, 2026
    The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)NalbuphinePhase 2RecruitingTrevi TherapeuticsJun 26, 2026
    Naltrexone for Nonsuicidal Self-InjuryNaltrexoneNot applicableNot yet recruitingSeoul National University HospitalJun 11, 2026
    Suzetrigine vs Norco-postoperative Mohs PainHydrocodonePhase 4Enrolling by invitationBaylor Research InstituteMay 8, 2026
    Cold and Compression After Rotator Cuff Repair (RCR)HydrocodoneNot applicableRecruitingOchsner Health SystemApr 8, 2026
    Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use DisorderNaltrexonePhase 3Not yet recruitingShenzhen Sciencare Medical Industries Co., Ltd.Feb 25, 2026
    Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord StimulationOxymorphone—RecruitingBrai²nFeb 17, 2026
    A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery PatientsNaltrexonePhase 1 / Phase 2Not yet recruitingMedical University of South CarolinaFeb 9, 2026
    An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServiceHydrocodonePhase 3Not yet recruitingUniversity of California, San FranciscoDec 22, 2025
    RCT: Suzetrigine vs Norco for Post-op PainHydrocodonePhase 4Not yet recruitingJacob LensingSep 29, 2025
    Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)OxymorphonePhase 4RecruitingDeventer ZiekenhuisJun 3, 2025
    Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid ExposureOxymorphonePhase 2Active, not recruitingNorthwestern UniversityJul 19, 2022

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095181, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.